The U.S. pharmaceutical supply chain is under sustained stress. Active drug shortages rose for the second consecutive quarter in 2026, reaching 223 in Q1. Sterile injectables are at highest risk: chemotherapy agents, sedation drugs, and IV fluids dominate the shortage list.
The USP 2025 report found that drug discontinuations surged 60 percent year-over-year. Price erosion makes it unviable for many manufacturers to maintain production lines. Approximately 15 percent of shortages involve controlled substances.
Generic drug pricing has reached levels where many products sell at or below cost. Sterile injectables require capabilities that take years to build. API supply chains depend on a small number of geographic regions, creating concentration risk.
Health systems are seeking alternative API sources. Suppliers with multi-site manufacturing can command premium pricing. Generic manufacturers are turning to CDMOs for surge production.
For B2B suppliers: invest in capacity for shortage-prone categories, build regulatory resilience, and develop long-term supply partnerships.
